Chen Wei team's new coronavirus antibody research breakthrough

screenshot of the article (available from the Military Medical Research Institute)S protein and 4A8 antibody structure map (military medical research institute for illustration)
Recently, Chinese scientists in the new coronavirus antibody research has made a major breakthrough, by the Chinese Academy of Engineering, military academy of military medicine research institute researcher Chen Wei led the team found the first target hedgehog protein N-side domain of the highly effective medium and monoclonal antibody. The findings were published online June 22 in Science. This is also the adenovirus vector recombination of the new crown vaccine in the world to enter phase II clinical trials, Chen Wei team made another important scientific research results.
the new crown pneumonia epidemic ravaged the world, the development of safe and effective vaccines and antibodies is a major challenge for scientists around the world. Vaccines are used for prevention in healthy populations, and antibodies are used for patients' special effects treatment, both of which work together to prevent and treat efficacy.
antibodies are a protective class of antibodies that the body should produce against primary stimuli. Currently, scientific research teams around the world focus on the drug design and structure of the new coronavirus, focusing on the binding domain of the new coronavirus prickly protein, while Chen Wei team by identifying the highly effective neutral monoclonal antibody of the n-side domain of the pyridron protein, found that the N-side domain is the new fragile surface of the new coronavirus protrusion protein, which provides a new effective target for therapeutic antibody and other drug design.
, Chen Wei's team, in collaboration with Zhou Qiang of West Lake University, used frozen electroscope technology to analyze the interaction interface between antibodies and hedgehog proteins with high precision, providing key information for clarifying their antiviral mechanisms. It was found that the antibody can play a high level of viral median effect when used alone, and can also be used as an efficient "cocktail" therapy in conjunction with the antibody for the binding domain of the subject. This provides a strong candidate for the treatment of neo-coronary pneumonia, as well as a new way of thinking for drug and surface vaccine design and the mechanism of action of new coronavirus targeting the N-side domain of pyrethroid protein.